Northern Lights Advisors
FATE icon

Northern Lights Advisors’s Fate Therapeutics FATE Stock Holding History

Northern Lights Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$23.8K Hold
10,040
– – 0.01% 73
2026
Q2 		$27.1K Hold
10,040
– – 0.01% 70
2026
Q1 		$12K Hold
10,040
– – 0.01% 56
2025
Q4 		$9.9K Buy
+10,040
New +$12.1K 0.01% 54

Other funds holding FATE

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Northern Lights Advisors's FATE Position: Q3 2026 in Review

Northern Lights Advisors held its Fate Therapeutics (FATE) position steady in Q3 2026 at 10,040 shares worth $23.8K. The position accounts for 0.01% of the portfolio, ranked #73.

Northern Lights Advisors first reported a position in FATE in Q4 2025 and has held it in 4 quarters since. The position peaked at $27.1K in Q2 2026. 55 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Northern Lights Advisors held 10,040 shares of Fate Therapeutics worth $23.8K as of Q3 2026.
  • Northern Lights Advisors left its Fate Therapeutics share count unchanged in Q3 2026.
  • Fate Therapeutics made up 0.01% of Northern Lights Advisors's portfolio in Q3 2026, its #73 holding.
  • Northern Lights Advisors first reported a position in Fate Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Northern Lights Advisors's Fate Therapeutics position peaked at $27.1K in Q2 2026.
  • 55 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Northern Lights Advisors's 13F filing for Q3 2026, filed 21 Oct 2026.